Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.3K
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

145
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
145
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

588
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
588
Development of Immunocompetence01:22

Development of Immunocompetence

533
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
533
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

47
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
47
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.3K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability.

Leukemia·2026
Same author

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate.

bioRxiv : the preprint server for biology·2025
Same author

Upfront menin-inhibitor resistance in multiply pretreated leukemias.

Experimental hematology·2025
Same author

Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy.

bioRxiv : the preprint server for biology·2025
Same author

Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.

Leukemia·2025
Same author

CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.

Journal for immunotherapy of cancer·2025
Same journal

Advances in Hemostasis Laboratory Testing.

Clinics in laboratory medicine·2026
Same journal

Extracellular Vesicles in Hemostasis.

Clinics in laboratory medicine·2026
Same journal

Thrombin Generation Assay: Ready for Prime Time.

Clinics in laboratory medicine·2026
Same journal

Viscoelastic Testing for the Laboratorian: Recent Advances and Practical Advice.

Clinics in laboratory medicine·2026
Same journal

Practical Recommendations for Harmonization of Hemostasis Testing Across Hospital Sites.

Clinics in laboratory medicine·2026
Same journal

The Role of Hypoxia in Vascular Endothelial Dysfunction and Venous Thromboembolism.

Clinics in laboratory medicine·2026
See all related articles

Related Experiment Video

Updated: Oct 26, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

83

Infant Acute Leukemia.

Gerald Wertheim1

  • 1Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, 5199b Main Building, 3401 Civic Center Boulevard, Philadelphia, PA 19104-4399, USA.

Clinics in Laboratory Medicine
|July 26, 2021
PubMed
Summary
This summary is machine-generated.

Infant acute leukemia is a rare, aggressive cancer. This review highlights its unique genetic and clinical features, presenting distinct treatment challenges in very young patients.

Keywords:
Acute leukemiaAcute megakaryoblastic leukemiaInfantsTransient myelopoiesis of Down syndrome

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.2K

Related Experiment Videos

Last Updated: Oct 26, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

83
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.2K

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Cancer Genetics

Background:

  • Infant acute leukemia is a rare and aggressive hematologic malignancy.
  • It shares similarities with adult acute leukemia but has distinct clinical and genetic features.
  • The extremely young age of affected infants poses significant treatment challenges.

Purpose of the Study:

  • To review the unique pathology of acute leukemia in infancy.
  • To detail the specific genetic characteristics of infant acute leukemia.
  • To discuss the clinical implications and challenges in treating this disease.

Main Methods:

  • Literature review of studies on infant acute leukemia.
  • Analysis of clinical and genetic data specific to infant cases.
  • Synthesis of current understanding of disease mechanisms and treatment strategies.

Main Results:

  • Infant acute leukemia exhibits unique genetic mutations not typically seen in older patients.
  • Distinct clinical presentations and disease trajectories are observed in infants.
  • These unique features necessitate tailored therapeutic approaches.

Conclusions:

  • Understanding the specific pathology and genetics of infant acute leukemia is crucial for effective treatment.
  • Further research into targeted therapies based on infant-specific genetic alterations is warranted.
  • Optimizing treatment strategies requires consideration of the unique biological and clinical aspects of this disease.